Will the EPO’s Enlarged Board of Appeal hear the Broad's CRISPR case?

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.
TidsskriftLife Sciences Intellectual Property Review (LSIPR)
Udgave nummer13/7 2018
Antal sider6
StatusUdgivet - 13 jul. 2018

ID: 199125991